Semantic and Syntactic Computerized Analysis of Free Speech
Launched by UNIVERSITY HOSPITAL, BREST · May 14, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain patterns in speech can help predict if someone is at high risk of developing schizophrenia, a serious mental health disorder. Researchers believe that by analyzing the way people talk, they can find early warning signs of a transition to psychosis in young individuals aged 15 to 30 who have shown signs of emotional distress, such as suicidal thoughts or behaviors. The goal is to create a reliable way to identify those at risk and improve early intervention strategies.
To participate in this study, eligible individuals must be between 15 and 30 years old and have experienced suicidal thoughts or behaviors that significantly impact their life. Participants will undergo assessments to analyze their speech patterns, but if they are taking certain medications that affect their thinking, they will need to pause these treatments for a week before joining the study. It’s important to note that individuals with a history of psychosis or those at risk of harming themselves may not be eligible. This study is currently recruiting participants, and everyone is welcome, regardless of gender.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Major and/or minor from 15 to 30 years old
- • Who alleged a suicidal gesture or idea or behavior that has repercussions in their emotional, social or professional life
- • If patients receive neuroleptic treatment that impairs cognitive abilities, a one-week wash-out period will be scheduled prior to assessment.
- Exclusion Criteria:
- • History of psychosis
- • Risk of self-harm or violence not compatible with outpatient treatment
- • QI\<70 (WAIS)
- • Neurological disorder or major health problem
- • Impossibility to interrupt neuroleptic treatment for one week
- • Refusal to participate
About University Hospital, Brest
The University Hospital of Brest is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. With a strong emphasis on interdisciplinary collaboration, the hospital serves as a hub for cutting-edge clinical trials aimed at improving treatment outcomes across various medical specialties. Leveraging its robust academic affiliations and state-of-the-art facilities, the University Hospital of Brest is committed to fostering scientific discovery and enhancing the quality of life for patients through evidence-based practices and pioneering research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brest, , France
Caen, , France
Paris, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials